ASH 2024: Awaiting Exciting Advancements in the Treatment of Chronic Lymphocytic Leukemia

Suchitra Sundaram, MD

November 27, 2024

Suchitra Sundaram, MD, describes the excitement around the American Society of Hematology (ASH) 2024 meeting in the chronic lymphocytic leukemia (CLL) community, with promising updates on innovative therapies and emerging biomarkers. Key presentations include new data on targeted therapy combinations in frontline CLL treatment, particularly Bruton tyrosine kinase (BTK) inhibitors and BCL-2 inhibitor combinations, with or without anti-CD20 monoclonal antibodies. Notably, the interim analysis of the phase 3 AMPLIFY trial will compare acalabrutinib-venetoclax with or without obinutuzumab vs chemoimmunotherapy, showing significant progression-free survival benefits.

Other intriguing developments include safety and efficacy data for zanubrutinib and sonrotoclax, as well as pirtobrutinib with venetoclax and obinutuzumab, demonstrating high undetectable minimal residual disease (MRD) rates. Additionally, promising data on BTK degraders for relapsed CLL and advancements in MRD-driven strategies, cellular therapies, and molecular insights will shape the future of personalized CLL treatment.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ASH 2024: Awaiting Exciting Advancements in the Treatment of Chronic Lymphocytic Leukemia - Medscape - Nov 27, 2024.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.